social anxiety disorder
Mental health · 2007–2014
No submission for this condition has carried consumer input, including the one made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| escitalopram Major depressive disorder, moderate to severe generalised anxiety disorder, and moderate to severe social anxiety disorder. | Jul 2014 | Recommended | none received |
| escitalopram oxalate Extension of listing to include moderate to severe social anxiety disorder (social phobia; SAD), as defined by DSM-IV criteria, in patients who have not… | Mar 2008 | Recommended with restriction | no section in document |
| escitalopram Extension of listing to include social anxiety disorder (social phobia) and generalised anxiety disorder in adults. | Mar 2007 | Not recommended | no section in document |
| escitalopram Extension of listing to include social anxiety disorder (social phobia) and generalised anxiety disorder in adults. | Mar 2007 | Not recommended | no section in document |
What the PBS pays
$32M in government benefit over 2024–25, across 2,832,198 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| escitalopram | $32M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.